Cephalon Beats Challenge To Narcolepsy Drug Patent

Law360, Los Angeles (April 1, 2013, 11:09 PM EDT) -- A Delaware federal judge on Saturday handed a win to Cephalon Inc. in its patent infringement suit aiming to block the sale of generic versions of the narcolepsy drug Nuvigil, rejecting generic-drug makers' claims that Cephalon's patent on the drug was invalid.

U.S. District Judge Gregory M. Sleet held that generic-drug makers Apotex Corp., Sandoz Inc. and others had failed to show that an expired Cephalon patent, U.S. Patent Number 4,927,855, anticipated or made obvious the current Nuvigil patent, and barred the defendants from selling generic...
To view the full article, register now.